Biotech News

Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Atea (AVIR)AteaEarnings

Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection Phase 3 C-FORWARD Trial for HCV on Track for Topline Results in Early 2027 Phase 1 Trial Evaluating AT-587 as Potential

Related news

Atea

Oral Antiviral Therapeutics Atea Pharmaceuticals develops oral antiviral therapies for serious viral diseases. Its pipeline is built around nucleotide and nucleoside analog chemistry and combination treatment strategies. Bemnifosbuvir and Ruzasvir The lead regimen combines the nucleotide polymerase inhibitor bemnifosbuvir with the NS5A...

Recent company news

Stock data

Close
3.93 USD
Market cap
341.72M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States